These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16920824)

  • 21. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase.
    Feng JY; Anderson KS
    Biochemistry; 1999 Jul; 38(29):9440-8. PubMed ID: 10413520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The majority of currently circulating human immunodeficiency virus type 1 clade B viruses fail to prime cytotoxic T-lymphocyte responses against an otherwise immunodominant HLA-A2-restricted epitope: implications for vaccine design.
    Altfeld M; Allen TM; Kalife ET; Frahm N; Addo MM; Mothe BR; Rathod A; Reyor LL; Harlow J; Yu XG; Perkins B; Robinson LK; Sidney J; Alter G; Lichterfeld M; Sette A; Rosenberg ES; Goulder PJ; Brander C; Walker BD
    J Virol; 2005 Apr; 79(8):5000-5. PubMed ID: 15795285
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous reverse transcriptase assays reveal synergy between combinations of the M184V and other drug resistance-conferring mutations in interactions with nucleoside analog triphosphates.
    Quan Y; Gu Z; Li X; Liang C; Parniak MA; Wainberg MA
    J Mol Biol; 1998 Mar; 277(2):237-47. PubMed ID: 9514745
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neutralizing antibodies directed against the V3 loop select for different escape variants in a virus with mutated reverse transcriptase (M184V) than in wild-type human immunodeficiency virus type 1.
    Inouye P; Cherry E; Hsu M; Zolla-Pazner S; Wainberg MA
    AIDS Res Hum Retroviruses; 1998 Jun; 14(9):735-40. PubMed ID: 9643373
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
    Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
    Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
    Turner D; Brenner BG; Routy JP; Petrella M; Wainberg MA
    New Microbiol; 2004 Apr; 27(2 Suppl 1):31-9. PubMed ID: 15646062
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced emergence of the M184V/I resistance mutation when antiretroviral-naïve subjects use emtricitabine versus lamivudine in regimens composed of two NRTIs plus the NNRTI efavirenz.
    McColl DJ; Margot N; Chen SS; Harris J; Borroto-Esoda K; Miller MD
    HIV Clin Trials; 2011; 12(2):61-70. PubMed ID: 21498149
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dominance of the E89G substitution in HIV-1 reverse transcriptase in regard to increased polymerase processivity and patterns of pausing.
    Quan Y; Inouye P; Liang C; Rong L; Götte M; Wainberg MA
    J Biol Chem; 1998 Aug; 273(34):21918-25. PubMed ID: 9705331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Insights into the molecular mechanism of inhibition and drug resistance for HIV-1 RT with carbovir triphosphate.
    Ray AS; Yang Z; Shi J; Hobbs A; Schinazi RF; Chu CK; Anderson KS
    Biochemistry; 2002 Apr; 41(16):5150-62. PubMed ID: 11955063
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CTL responses of HLA-A2.1-transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1.
    Shirai M; Arichi T; Nishioka M; Nomura T; Ikeda K; Kawanishi K; Engelhard VH; Feinstone SM; Berzofsky JA
    J Immunol; 1995 Mar; 154(6):2733-42. PubMed ID: 7533182
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiretroviral drug resistance mutations sustain or enhance CTL recognition of common HIV-1 Pol epitopes.
    Mason RD; Bowmer MI; Howley CM; Gallant M; Myers JC; Grant MD
    J Immunol; 2004 Jun; 172(11):7212-9. PubMed ID: 15153547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular mechanism of dioxolane nucleosides against 3TC resistant M184V mutant HIV.
    Chong Y; Chu CK
    Antiviral Res; 2004 Jul; 63(1):7-13. PubMed ID: 15196815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
    von Wyl V; Ehteshami M; Symons J; Bürgisser P; Nijhuis M; Demeter LM; Yerly S; Böni J; Klimkait T; Schuurman R; Ledergerber B; Götte M; Günthard HF;
    J Infect Dis; 2010 Apr; 201(7):1054-62. PubMed ID: 20170373
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
    Zaccarelli M; Perno CF; Forbici F; Cingolani A; Liuzzi G; Bertoli A; Trotta MP; Bellocchi MC; Di Giambenedetto S; Tozzi V; Gori C; D'Arrigo R; De Longis P; Noto P; Girardi E; De Luca A; Antinori A
    Antivir Ther; 2003 Feb; 8(1):51-6. PubMed ID: 12713064
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Might the M184V substitution in HIV-1 RT confer clinical benefit?
    Petrella M; Wainberg MA
    AIDS Rev; 2002; 4(4):224-32. PubMed ID: 12555696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lamivudine can exert a modest antiviral effect against human immunodeficiency virus type 1 containing the M184V mutation.
    Quan Y; Brenner BG; Oliveira M; Wainberg MA
    Antimicrob Agents Chemother; 2003 Feb; 47(2):747-54. PubMed ID: 12543687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enhanced in vitro potency and in vivo immunogenicity of a CTL epitope from hepatitis C virus core protein following amino acid replacement at secondary HLA-A2.1 binding positions.
    Sarobe P; Pendleton CD; Akatsuka T; Lau D; Engelhard VH; Feinstone SM; Berzofsky JA
    J Clin Invest; 1998 Sep; 102(6):1239-48. PubMed ID: 9739058
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of Human Immunodeficiency Virus Type 1 Resistance to 4'-Ethynyl-2-Fluoro-2'-Deoxyadenosine Starting with Wild-Type or Nucleoside Reverse Transcriptase Inhibitor-Resistant Strains.
    Cilento ME; Reeve AB; Michailidis E; Ilina TV; Nagy E; Mitsuya H; Parniak MA; Tedbury PR; Sarafianos SG
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0116721. PubMed ID: 34516245
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential maintenance of the M184V substitution in the reverse transcriptase of human immunodeficiency virus type 1 by various nucleoside antiretroviral agents in tissue culture.
    Petrella M; Oliveira M; Moisi D; Detorio M; Brenner BG; Wainberg MA
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4189-94. PubMed ID: 15504840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review).
    Menéndez-Arias L; Mas A; Domingo E
    Viral Immunol; 1998; 11(4):167-81. PubMed ID: 10189185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.